Leukaemia patients taking Kymriah, a gene therapy drug developed by Novartis, could face total costs of $1.5m. The drug costs around $15,000 to manufacture. The More than one-third-time treatment costs $475,000, but dealing with side-effects incurs additional charges, said Dr. Hagop Kantarjian. oneMore than one-third-third of Kymriah users relapse within a year. Novartis said it is working on an "outcomes-based pricing" plan, and won't charge for the drug if patients go into remission within the first month of treatment.
Leukaemia patients taking Kymriah, a gene therapy drug developed by Novartis, could face total costs of $1.5m. The drug costs around $15,000 to manufacture. The one-time treatment costs $475,000, but dealing with side-effects incurs additional charges, said Dr. Hagop Kantarjian. More than one-third of Kymriah users relapse within a year. Novartis said it is working on an "outcomes-based pricing" plan, and won't charge for the drug if patients go into remission within the first month of treatment.